Board of Directors
Timothy J. Wiegand, MD, FACMT, FAACT, DFASAM
Timothy J. Wiegand, MD, FACMT, FAACT, DFASAM serves as Associate Professor of Emergency Medicine and the Director of Addiction-Toxicology and the Toxicology/Addiction Consult Service at Strong Memorial Hospital and the University of Rochester Medical Center. Dr.Wiegand started treating addiction nearly 20 years ago and has since worked to bridge the fields of addiction medicine and medical toxicology. In addition to emergency department, hospital, and clinic work treating drug exposures, intoxication, and withdrawal, and assisting with pain management for patients maintained on Medications for Opioid Use Disorder in the emergency department, hospital, and perioperative setting, Dr. Wiegand is also involved with medical education and research in toxicology and addiction.
Dr. Wiegand is the Program Director for the UR Emergency Medicine & Toxicology-based Addiction Medicine Fellowship Program, and he is core faculty for the Emergency Medicine residency at Strong Memorial Hospital. He lectures locally, regionally, nationally, and internationally on topics in addiction medicine and medical toxicology. Dr. Wiegand currently serves on the ASAM Board of Directors as Vice President and has served two terms as a board member of the American College of Medical Toxicology. He has also been Treasurer and Finance Chair for the Medical Toxicology Foundation and he is a Past President of the New York Society of Addiction Medicine.
Prior to serving as Vice President of ASAM, Dr. Wiegand was an At-Large Board Director for ASAM. He has also served on the nominations committee and participated in numerous other groups including expert panels, in the development of educational content, and in the creation of Position Statements and Guidelines (e.g., Drug Testing in Clinical Addiction Medicine and the Stimulant Use Disorder Guidance documents).
Dr. Wiegand regularly presents at the ASAM Annual Conference, through lectures and workshops, as well as presenting posters and mentoring young investigators. In addition to the annual conference Dr. Wiegand has presented at the Board Review Course and for live webinars and the eLearning platform on educational content related to pain and OUD, drug testing, and other topics. He also leads and moderates the monthly Addiction Toxicology Case Conference featuring live interactive discussion with expert panelists on cases that fall into the intersection of Addiction Medicine and Medical Toxicology.
Dr. Wiegand served as President of NYSAM during the COVID19 pandemic and helped guide the NYSAM chapter into its first virtual annual conference and public policy day. NYSAM has since expanded virtual education into other activities including a Cannabis Webinar series which he developed and curates content for. He also led the transition to new administrative support through the New York state Medical Society and he oversaw a Bylaws review and update which expanded the NYSAM Board, adding a trainee board position (student, resident or fellow), among other updates.
Dr. Wiegand actively mentors ASAM members. His fellows and mentees have gone on to take leadership positions within NYSAM and ASAM and in their community or institutions. In recognition of his service and leadership at the 2022 ASAM Annual Conference Dr. Wiegand was awarded the ASAM Annual Award which recognizes and honors an individual for outstanding contributions to the growth and vitality of ASAM, for thoughtful leadership in the field, and for deep understanding of the art and science of addiction medicine, as well as for expanding the frontiers of the field of addiction medicine and broadening our understanding of the addictive process through research and innovation.
Candidate Questionnaire Reponse
1. What have been your greatest contributions to ASAM or to the field of addiction medicine over the last 10 years?
I have been active within ASAM in a variety of volunteer positions. Most recently I have served on the Executive Counsel as the Vice President of ASAM and I will be finishing a 2 year-term this coming April. It has been a pleasure and honor to serve ASAM and our membership in this capacity. I have worked closely with the Treasurer, Secretary, President Elect and President as well as the Executive Director and ASAM Leadership and Administrative Support on a variety of critical activities from educational planning and approval, advocacy efforts, legislative support, social justice and diversity initiatives, in addition to planning ASAM activities as the pandemic evolved and quick decisions needed to be made. This experience has led to an appreciation for members’ commitment to ASAM, the outstanding staff and administrative support ASAM has been able to rely on. It has also reminded me of the importance of ASAMs obligations to the patients and public health we serve as a professional organization and as individual Addiction Medicine specialists.
Prior to serving as Vice President, I was an At-Large Board Director for ASAM. I have served on the nominations committee and participated in numerous other groups including expert panels, in the development of educational content and in the creation of Position Statements and Guidelines. Some of the things I have formally worked on are the Drug Testing in Clinical Addiction Medicine Guidance document, as an author and expert panelist, and I was lead author for the Pocket Guide to Drug Testing in Clinical Addiction Medicine. I’m currently a member of the Expert Panel convened to develop Guidance document on the treatment of Stimulant Use Disorder (StUD), and as a member of the Board I have reviewed and provided feedback and approval for statements ASAM has published over the past several years.
I have presented at the Annual Conference for nearly ten years, giving a variety of plenary sessions, workshops and focus sessions as well as presenting posters and mentoring young investigators. I am part of a Medical Toxicology and Addiction Medicine group that brings together the intersection of Addiction Medicine and Medical Toxicology (Addiction Toxicology) with several presentations each year. These sessions are often among the highest ranked by attendees at the annual conference. Naloxone, Fentanyl, Designer Drugs, ED and hospital care of patients with addiction and Substance Use Disorders (SUDs), and sessions on the treatment of Severe Agitated Delirium, or “Excited Delirium”, have been some of the topic areas I’ve either led presentations or been part of the group presenting at the annual conference. In addition to presentations for the Annual Conference and State Chapters (I’ve coordinated and presented at the NYSAM Toxicology Panel since its inception nearly ten years ago). I have organized the NYSAM Poster competition which each year supports several awardees to attend and present at NYSAM conference. I have presented at the Board Review Course on Toxicology and Pharmacology and Drug Testing, and on educational content related to the Opioid Use Disorder Guidelines 2020 update on Pain and OUD. I also lead and moderate the monthly Addiction Toxicology Case Conference, held the first Friday of each month featuring live interactive discussion with expert panelists and the audience on cases that fall into the intersection of Addiction Medicine and Medical Toxicology. During COVID19 this focused on nuances of care required due to pandemic disruption of healthcare delivery and regulatory changes, and I led sessions on the Treatment of Substance Use Disorder during COVID19. These sessions have been recorded and are available to members of both ASAM and the American College of Medical Toxicology (ACMT).
In addition to national leadership and service I have been very active at the state and chapter level where I currently serve as the Immediate Past President and Chair the Nominations Committee of the New York Society of Addiction Medicine (NYSAM). I served during the COVID19 pandemic and guided our chapter into its first virtual annual conference and public policy day.
NYSAM has since expanded virtual education into other activities including a Cannabis Webinar series, which I organized and developed content for. I also led the transition to new administrative support through our state Medical Society. NYSAM has also incorporated new educational content delivery and IT expertise which has expanded our reach and ability to work with our membership through website development and social media. As President of NYSAM I also oversaw a Bylaws review and update which expanded our Board, formally adding a trainee board position (student, resident or fellow) among other updates.
I have been a fellowship director and had graduate fellows go on to take leadership positions both within NYSAM and ASAM. I mentored Dr. Jade Malcho as she was awarded the Young Investigator Award for best poster 2020 on buprenorphine micro induction. Dr. Malcho was the early career physician for the NYSAM Board 2020-2022. Another fellowship graduate is currently serving on the NYSAM Board as an at-large director.
Finally, I am active with mentoring several ASAM members both formally and informally, related to medication use and pharmacology, practice and professional development, billing and reimbursement and other areas.
At the 2022 ASAM Annual Conference I was awarded the ASAM Annual Award which recognizes and honors an individual for outstanding contributions to the growth and vitality of ASAM, for thoughtful leadership in the field, and for deep understanding of the art and science of addiction medicine, as well as for expanding the frontiers of the field of addiction medicine and broadening our understanding of the addictive process through research and innovation.
2. How would your election to the ASAM Board of Directors benefit ASAM and the field of addiction medicine?
The Treasurer position is a critical position on the ASAM Board of Directors and the Executive Counsel. My past experience as Vice President has given me insight into the EC dynamics and responsibilities of an EC member and I have learned how critical having someone who is versed in finance, able to work with ASAM administrative support and accounting as well as outside experts in accounting so that ASAM continues to show financial stability and growth. This is critical to our mission as a membership run organization. I have prior experience serving as Treasurer for the NYSAM Chapter which is the second largest Chapter within ASAM. I have served as Treasurer and Chaired the Finance Committees for other non-profit Board entities, including the Medical Toxicology Foundation a 501C3 entity. If elected treasurer I will work with the experienced and dedicated staff and other volunteer members of the Finance Committee to best serve ASAM and our membership in this critical position.
As a member of the EC, beyond the role of treasurer I have made it clear I see having the specialty of addiction medicine available is critical for public health and for the health care system at all levels. It is a critical expertise for improving health and outcomes and in the prevention of disease and it as an opportunity for professional growth for physicians both as a primary specialty or to complement a primary medical specialty. I was awarded the 2022 ASAM Annual Award based on my work bridging Medical Toxicology and Addiction Medicine. Over 20% of Board-Certified Medical Toxicologists are now also dual boarded in Addiction Medicine. A large portion of my professional work is focused on creating visibility, education, mentoring and other work in the Addiction/Toxicology interface and I look forward to continuing this as well as expanding into other areas within healthcare and with other medical specialties.
ASAM has incredible potential and opportunity related to advocacy and legislative efforts with regard to expanding access to care for treatment of substance use disorders and addiction as well as for social justice and diversity within medicine and society. I have been impressed with and very pleased to have helped ASAM first on the Board and Executive Committee determine response and priorities in these areas. I’ve also been very pleased with ASAMs work and development of position statements and general response over the past several years as events dictated our organization respond (response to the death of George Floyd, healthcare inequities exacerbated by COVID19, the disparities increasingly clear as the opioid overdoses continue to climb are some examples). I look forward to continuing to serve ASAM in this area and have appreciated the commitment to other board members and staff. On the Nomination Committee I was involved with the development of a new annual award for “Promotion of Inclusion, Diversity, Equality and Justice in Addiction Medicine. Nominations for the inaugural award for 2023 had recently closed.
I offer diversity of specialty background to the ASAM EC having Medical Toxicology and Clinical Pharmacology training as my primary specialty. As changing drug markets and also treatment options has dictated a nuanced understanding of pharmacology to most safely and effectively treat patients with SUDs and addiction, in particular as medications are initiated in the area of fentanyl, as Addiction medicine specialist become increasingly relevant in the ED and hospital setting helping with pain and perioperative management and in drug testing guidance and interpretation having the toxicology knowledge enhances my expertise and value as an Addiction Medicine specialist and also Board member.
Most important, however, for the Treasurer position, is the experience I’ve had serving ASAM, NYSAM, and other organizations where I’ve served on the finance committee or as Treasurer, and the experience, track record and willingness I have demonstrated to work with and listen to the expertise that has helped guide ASAM to current financial position.